ONL Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in Michigan, United States, focused on the development of novel therapies for retinal diseases.
Subscribe to see ONL Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ONL Therapeutics, Inc. is a biotechnology company headquartered in Ann Arbor, United States. It has raised at least $110.1M across the 8 funding rounds on record. Its most recent funding round raised $60M in September 2024. Xcout tracks 11 named people at ONL Therapeutics, Inc., including David Esposito (CEO & President).
As of 16 November 2026. Source: Xcout Intel.
5 more named people on record for ONL Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
At least $110.1M raised across the 8 rounds on record. The 6 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $60M | — | |
| SEC Form D filing | $10M | — | |
| SEC Form D filing | $5M | — | |
| SEC Form D filing | $26.8M | — | |
| SEC Form D filing | $2M | — | |
| SEC Form D filing | $3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of ONL Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Stargazer Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing novel treatments for rare eye diseases, including Stargardt disease. The company advances clinical-stage pharmaceutical candidates through specialized clinical trials.
Memento Medicines, Inc. is a privately held biotechnology company headquartered in Boston, Massachusetts, focused on developing novel biologic therapies for retinal diseases.
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The company works to deliver advanced retinal gene therapies to patients experiencing blindness.
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, with additional offices in Baltimore, Maryland, focused on developing medicines for ocular diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about ONL Therapeutics, Inc.? Suggest a correction · Work at ONL Therapeutics, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.